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DermaseptinTo enable selection and characterization of highly potent pore-forming peptides, we developed a set of novel
assays to probe 1) the potency of peptide pores at very low peptide concentration; 2) the presence or absence
of pores in membranes after equilibration; 3) the interbilayer exchangeability of pore-forming peptides; and
4) the degree to which pore-forming peptides disrupt the bilayer organization at equilibrium. Here, we use
these assays to characterize, in parallel, six membrane-permeabilizing peptides belonging to multiple classes.
We tested the antimicrobial peptides LL37 and dermaseptin S1, the well-known natural lytic peptides melit-
tin and alamethicin, and the very potent lentivirus lytic peptides LLP1 and LLP2 from the cytoplasmic domain
of HIV GP41. The assays veriﬁed that that the antimicrobial peptides are not potent pore formers, and form
only transient permeabilization pathways in bilayers which are not detectable at equilibrium. The other pep-
tides are far more potent and form pores that are still detectable in vesicles after many hours. Among the pep-
tides studies, alamethicin is unique in that it is very potent, readily exchanges between vesicles, and disturbs
the local bilayer structure even at very low concentration. The equally potent LLP peptides do not exchange
readily and do not perturb the bilayer at equilibrium. Comparison of these classes of pore forming peptides in
parallel using the set of assays we developed demonstrates our ability to detect differences in their mecha-
nism of action. Importantly, these assays will be very useful in high-throughput screening where highly po-
tent pore-forming peptides can be selected based on their mechanism of action.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Peptides that self-assemble into pores or channels across mem-
branes have potential utility as biosensor platforms [1,2], targetable
cytotoxins [3,4], chemo-sensitizing agents [5], and exogenous ion chan-
nels, as suggested for the treatment of cystic ﬁbrosis, for example [6]. In
order to obtain peptides with speciﬁc properties, one must be able to
design them de novo, rationally engineer knownpore-forming peptides,
or select peptideswith the desired properties from peptide libraries. For
example, designing an ideal biosensor peptide would require the iden-
tiﬁcation of a peptide that self-assembles into long-lived, transmem-
brane pores that remain open and stably inserted in membranes [7,8].
While there are many membrane permeabilizing peptides and a range
of mechanisms by which such peptides can act [9-12], there are few, if
any, that are known to self-assemble into long-lived multimeric, trans-
membrane pores. Most pore forming peptides are in dynamic equilibri-
um between free and bound states and/or between monomeric and
oligomeric states in the membrane [13,14]. Therefore, the design or se-
lection of a stable pore-forming peptide would be a signiﬁcant advance
in bioengineering. But there are barriers to this goal arising, in part, from).
rights reserved.the knowledge gap in the fundamental principles of folding and assem-
bly of peptide pores in membranes. Furthermore, the lack of simple an-
alytical tools for characterizing pore-forming peptides at very low
peptide concentrations (≤0.1 mol% peptide) where a useful biosensor
would be active has hindered the design and selection of peptides
with such properties.
A long-term goal of our work is to discover peptides that assemble
into such long-lived pores in membranes by selecting them from com-
binatorial peptide libraries using high-throughputmethods [15-18]. For
this purpose we have designed a novel set of analytical tools that can be
used to help identify such peptides bymeasuring four properties at very
low peptide to lipid ratio: 1) the overall potency of a peptide pore-
former in lipid vesicles; 2) the continued existence (or absence) of
peptide pores at equilibrium; 3) the interbilayer exchangeability of
pore-forming peptides; and 4) the degree to which pore forming pep-
tides disrupt the bilayer organization at equilibrium. A membrane
pore could theoretically be detectable at concentrations as low as to
1–2 pores (i.e. 4–20 peptides) per vesicle. Furthermore, a long-lived
pore that could potentially be useful as a biosensor will, by deﬁnition,
remain active in a membrane at equilibrium, will not perturb the lipid
organization, and will not exchange in and out of bilayers on the time
scale of at least a few hours.
In thework presented here, we use a set of analytical toolswe devel-
oped to characterize, in parallel, the behavior of six known α-helical,
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peptides consist of cationic host-defense antimicrobial peptides as well
as amphipathic α-helical pore forming peptides, including the well-
known peptides, alamethicin andmelittin. The experiments, performed
at peptide concentrations as low as 50 peptides/vesicle, reveal observ-
able differences in the behavior of the different classes of pore-
forming peptides, and demonstrate ways in which one could select for
particular mechanisms of action in high-throughput screens. The cat-
ionic antimicrobial host defense peptides are inactive at low peptide
to lipid ratios, and show little or no evidence of equilibrium pores at
any concentration. The lytic helical peptides, on the other hand, form
explicit pores in vesicles that can be detected at equilibrium, even at
very low peptide concentration.While it is known that there are multi-
ple mechanisms of membrane permeabilization by peptides, members
of multiple classes have rarely been studied in parallel using the same
techniques. In the parallel studies described here, we demonstrate
that the assays we describe here can readily distinguish between differ-
ent mechanisms of peptide pore formation in membranes, and can be
used to select peptides from libraries that act via particularmechanisms
to permeabilize membranes.
2. Materials and methods
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) and 1,2,
dioleoyl-sn-3-glycero-phosphoethanolamine-N-(7-nitro-2-1,3-ben-
xodiazol-4-yl) (NBD-PE) were purchased from Avanti Polar Lipids.
Alamethicin, melittin, dermaseptin S1, dipicolinic acid, TbCl3, and
reduced triton-X 100 were from purchased from Sigma-Aldrich
Chemical Co. LL-37was purchased from Innovagen. NBD-labeled lysoli-
pids were synthesized for the ﬂip-ﬂop assay. Brieﬂy, NBD-succinamidyl
ester was coupled to lyso-phosphatidylethanolamine (lyso-PE) and pu-
riﬁed by thin layer chromatography (TLC). The NBD-labeled lysolipid
end product was conﬁrmed by MALDI-MS. With the exception of ala-
methicin, peptide stocks were stored in H2O or buffer. Concentrated
alamethicin stocks were stored in methanol and were diluted into
buffer for all experiments.
2.1. Liposome preparation
Lipid aliquots in chloroform were vacuum dried overnight, sus-
pended in buffer and freeze–thawed twenty times. Large unilamellar
vesicles (LUVs) were formed by extruding the lipid suspension ten
times through two stacked 100 nm nucleopore polycarbonate ﬁlters
[19]. For the two step assay, vesicles were prepared with 1 mol%
headgroup-labeled diacyl NBD-PE. The buffer consisted of 50 mM
TbCl3, 100 mM sodium citrate, and 10 mM TES at pH 7.2. After the ex-
trusion process, liposomes were separated from external terbium via
gel ﬁltration chromatography [16,17] using a solution containing
300 mMNaCl to balance the ionic strength of TbCl3. The buffer for all ex-
periments contained 300 mMNaCl and 10 mM TES, pH 7.2. For leakage
assays 50–100 μM of DPA was added to the buffer. For ﬂip-ﬂop experi-
ments, the NBD-labeled lyso-lipids were dried together with POPC and
POPG at 1 mol% NBD-lysoPE. Acceptor vesicles in the ﬂip-ﬂop assay
were prepared with 1 mol% N-lissamine rhodamine B-labeled-DOPE
as a collisional quencher of NBD-lysolipid. Lipid concentration was de-
termined by the Bartlett assay.
2.2. Two step assay
The two step assay was designed to measure, in the same vesicles,
membrane permeabilization and long-term access to vesicle interior
through equilibrium peptide pores. Large unilamellar vesicles made
from POPC or from 90/10 POPC/POPG containing entrapped terbium
and 1% NBD-labeled diacyl phospholipids were incubated for at
least 8 hours with peptide and external dipicolinic acid in 96-wellmicroplates. Peptide concentration was 1 μM and terbium/NBD vesi-
cles were always at 200 μM ﬁnal concentration. To change the strin-
gency (i.e. the overall P:L ratio) liposomes without Tb3+ or NBD
were added. Wells with liposomes only were used as negative con-
trols, and wells with liposomes plus 0.1% ﬁnal concentration of re-
duced Triton-X 100 detergent were used as positive controls. After
incubating for at least 8 hours to allow the system to reach equilibri-
um, terbium leakage was measured, followed by measurements of in-
terior access by dithionite quenching of NBD. Measurements were
performed on a Synergy-2 Biotek microplate reader. DPA–Terbium
complex ﬂuorescence was detected with an excitation ﬁlter of 284/
11 (band pass maximum/half-width) and emission ﬁlter of 530/25,
using a xenon ﬂash lamp with 250 μs delay and 1 ms retention time.
Sensitivity was adjusted so that the positive controls' ﬂuorescence
was roughly 30% of the instrument maximum. The percentage of ter-
bium released from samples was determined using the equation:
% Leakage ¼ Fsample−Fbackground
FTriton−Fbackground
 !
 100%
Where Fsample is the ﬂuorescence intensity of the sample, Fbackground
is the ﬂuorescence intensity of lipids only as the negative control, and
FTriton is the ﬂuorescence intensity of a separate sample lysed with
triton-X detergent as the positive control. In the second step of the
assay, the initial ﬂuorescence intensity of the NBD-labeled lipids was
recorded using 480/25 excitation and 530/25 emission ﬁlters. Sodium
dithionite (10 μL of a freshly prepared at 0.6 M in 1.0 M sodium phos-
phate, pH 10.0 for each experiment) was added to each well and then
the ﬂuorescence wasmeasured every 5 min for up to 70 min. NBD ﬂuo-
rescence was rapidly quenched by dithionite with a half time of
5–10 min. Intensity reached a plateau by 30–60min. In the presence
of Triton X-100, the NBD intensity was quenched completely. The per-
cent of NBD quenched was calculated using the equation:
%Quenched ¼ 1− F final−Fbackground
F Initial−Fbackground
 !
 100%
2.3. Flip-ﬂop Assay
Transbilayer lipid movement (ﬂip-ﬂop) was detected by a modiﬁ-
cation of an assay that is described in detail elsewhere [20]. Brieﬂy,
we assessed ﬂip-ﬂop in POPC vesicles by monitoring the exchange
of NBD-lysolipid between vesicles. NBD-lysolipids on the outer
monolayer of a vesicle exchange rapidly between vesicles through
the aqueous phase. Inner monolayer lipids are not normally ex-
changeable into other vesicles due to very slow equilibration between
monolayers. Thus, normally only about half the lysolipid is exchange-
able. If a peptide or other molecule perturbs the bilayer enough to in-
duce rapid transbilayer lipid exchange, then all of the NBD-lysolipid
will be exchangeable. Here we performed ﬂip-ﬂop experiments to ex-
amine the degree of bilayer disruption by pore-forming peptides at
equilibrium. The ﬂuorescence of NBD-lysolipid was measured on a
SLM-Aminco ﬂuorescence spectrometer with excitation and emission
wavelengths at 464 nm and 532 nm respectively. All assays were at P:
L=0.001 with 800 nM peptide, 160 μM POPC LUVs symmetrically la-
beled with lyso-NBD and 640 μM non-ﬂuorescent POPC LUVs. After
equilibration with peptide, ﬂuorescence was monitored for 2–5 min
at the initial conditions, and then 250 μM rhodamine-labeled POPC li-
posomes were added and the ﬂuorescence was recorded for 10 min.
Exchange of the NBD-lysolipid in the outer monolayer into the rhoda-
mine vesicles caused a decrease in ﬂuorescence due to quenching. As
a positive control for ﬂip-ﬂop (i.e. exchange of outer and inner mono-
layer NBD-lysolipid) we added 0.6 nmol alamethicin (P:L=0.006) at
about 10 min and recorded an additional 15 min of data. Previous
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induces rapid ﬂip-ﬂop immediately upon addition to liposomes
[20,21].
2.4. Incremental leakage assay
The terbium-leakage assay described above was modiﬁed to ad-
dress whether a peptide's pore-forming activity involves a dynamic
process of peptide equilibration into and out of membranes or wheth-
er the peptide pores, once formed, are stably inserted into mem-
branes. To examine this, the incremental assay was implemented to
detect pore-forming activity in sequential additions of liposomes.
Vesicles (9:1 POPC:POPG) with entrapped terbium were added to
the same peptide solution in three separate additions. The lipid con-
centration was constant at P:L=0.001 (1:1000) for each increment
except for melittin which was studied at P:L=0.005 (1:200) for
each increment, due to its lower activity. Peptides were allowed at
least 8 hour incubation before each measurement. With each volume
of liposomes added, the leakage activity was determined using the
following equation:
% Leakagei ¼ F
i
sample−Fi−1sample−Fibackground
Fi
Triton
−Fi−1Triton−Fibackground
 !
 100%
Fi is the ﬂuorescence of sample well with i lipid additions, Fi−1 is
the ﬂuorescence of same sample with i−1 lipid additions (i.e. before
the ith addition). FTriton is the value of a detergent lysed control sam-
ple for the I or the i−1 lipid addition, measured in a different sample.
Fbackground is the background intensity from the wells of liposomes
only of the ith lipid addition. All experiments were performed in trip-
licate and averaged.
2.5. Serial dilution assay
The pore-forming activity of peptides requires them to partition
into membranes and disrupt the lipid bilayer. In the simplest model
of pore-formation, the peptide activity should depend on how much
peptide is bound to membrane per unit area, i.e. bound peptide to
lipid ratio (PB:L). Experimentally, one should be able to use the
mole fraction partition coefﬁcient (KX) and the P:L ratio to ascertain
the critical bound peptide-to-lipid ratio (P:LB) for alamethicin activi-
ty. We used the serial dilution assay to test this idea. In this assay,
alamethicin was added to terbium containing POPC/POPG (90/10)
LUVs in 96-well microplates. Each column had a ﬁxed total P:L ratio,
but from the top to bottom rows had decreasing overall peptide and
overall lipid concentrations. The intensity for complete leakage was
determined by adding Triton X-100 to control wells containing the
appropriate amount of lipid vesicles. As a control for loss of peptide
at low concentration due to adhesion to the wells of the 96 well
plates, we repeated the serial dilution assays in the presence of bo-
vine serum albumin (BSA), which blocks peptide binding sites, and
found no difference in the results.
3. Results
3.1. The peptides studied
The goals of this work were to develop a set of novel assays that
will enable us to explore the detailed mechanism of peptide pore-
formation and to select peptides with particular mechanisms of ac-
tion from peptide libraries. Here we use the assays that we developed
to characterize, in parallel, six α-helical, membrane permeabilizing
peptides that cover a range of proposed mechanisms of action. First
we used two well-characterized antimicrobial host-defense peptides;
human LL37 and the tree frog peptide dermaseptin S1. We and othershave suggested that this class of peptides permeabilize membranes
by causing transient bilayer destabilization without formation of ex-
plicit pores [10,12]. We also studied four lytic helical peptides that
have been proposed to form explicit pores in membranes: Alamethicin,
a fungal peptaibol [13,22], melittin, the lytic peptide form European
Honey Bee venom [23], and the lentivirus lytic peptides LLP1 and
LLP2 from the cytoplasmic domain of HIV GP41 which have been
shown to be highly potent pore-formers [24]. The chemical and struc-
tural properties of the six peptides studied in this work are given in
Table 1.3.2. Potent, equilibrium peptide pores in vesicles: The two step assay
For thiswork, we developed the orthogonal, two step assaywhich can
be used to independently assess the potency of a pore-forming peptide
in lipid vesicles (step one) and the continued presence of peptide pores
at equilibrium (step two). The twomeasurements aremade sequentially
in the same vesicles. The second step is important because it distin-
guishes true pore-forming peptides from interfacially-active peptides,
such as antimicrobial peptides [10,25], which often cause leakage only
transiently (i.e. only for a short time immediately after addition to
vesicles). The second step does not distinguish between stable, long-
lived pores and dynamic pores that ﬂuctuate in and out of existence
with short lifetimes. However it does assess whether or not a leakage
pathway (of any type) exists in the membrane at equilibrium. For the
purposes of these experiments we deﬁne equilibrium as at least
8 hours after addition of peptide to vesicles. Given the fact that binding,
leakage and structure transitions in vesicles usually take place on time
scales of tens ofminutes after addition [26,27] this is a reasonable deﬁni-
tion. In the ﬁrst step of the assay, peptide-induced leakage from vesicles
is assessed using the binary terbium/dipicolinic acid assay we have de-
scribed elsewhere [17,18]. Vesicles have entrapped terbium (Tb3+)
which can form a luminescent complex with the aromatic chelator dipi-
colinic acid (DPA), present in the external solution; but only if the mem-
branes are permeabilized. In the second step of the assay, access to lipid
headgroups on the innermonolayer of the same vesicles is assessed after
equilibration by measuring the ability of the membrane-impermeant re-
ducing agent dithionite (M.W. 128 Da) to chemically quench the dye
NBD linked to lipids that are symmetrically distributed on the inner
and outer leaﬂets of the bilayer vesicle. In vesicles without peptide or
without pores, only dye-labeled lipids exposed on the outer leaﬂet
(~55% of the total lipid) can be quenched. Quenching of the interior
NBD lipids after equilibration can occur only if a peptide pore allows
dithionite access to inside of the vesicle, or if a peptide disturbs the bilay-
er enough to allow transbilayer equilibration (ﬂip-ﬂop) of NBD-lipids to
the outer monolayer.
In Fig. 1 we show the results of two step assays performed on the
six membrane-permeabilizing peptides studied. For all measure-
ments peptide concentrations were constant at 1 μM and the lipid
concentration was varied to achieve different peptide to lipid (P:L)
ratios as shown. We used vesicles made from zwitterionic POPC lipids
and vesicles that also contain 10 mol% anionic POPG. Differences be-
tween the two lipid compositions were minor. The two antimicrobial
peptides, LL37 and dermaseptin S1 caused measurable leakage only at
the highest P:L ratios studied and allowed essentially no access to the
vesicle interior at equilibrium. The only exception was dermaseptin
S1 at the highest P:L studied, P:L=0.02 (1:50), and only in PG-
containing vesicles. Under these conditions high leakage and high ac-
cess to NBD lipids were observed. However, at this high P:L ratio,
detergent-like, physical disruption of vesicle architecture is possible
[28], which would also allow access to interior NBD-lipids. In support
of this idea, dermaseptin S1, at P:L=0.005 (1:200), causes nearly 80%
leakage while allowing no access to the vesicle interior at equilibrium.
Equilibrium pores are not required for the permeabilizing activity of
dermaseptin or LL37.
Table 1
Properties and sequences of the peptides studied.
Peptide Organism Length (aa) Charges Pos/Neg 2° Structure Amino acid sequence
LL37 Human 37 +12/−6 α LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Dermaseptin S1 Tree Frog 34 +5/−2 α ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ
Melittin Honey Bee 26 +6/0 α GIGAVLKVLTTGLPALISWIKRKRQQ-amide
LLP1 HIV 28 +8/−3 α RVIEVVQGACRAIRHIPRRIRQGLERIL
LLP2 HIV 20 +5/−3 α YHRLRDLLLIVTRIVELLGR
Alamethicin fungus 20 +0/−0 α Ac-UPUAUAQUVUGLUPVUUQQF-OH (U=AiB)
Properties of the peptides studied in this work. Charges include the amino and carboxyl termini, where appropriate, but do not include histidine. All of the peptides have α-helical
secondary structure when bound to membranes. Alamethicin is secreted as a heterogeneous mixture of closely related peptides. Commercial sources contain peptides either pre-
dominantly from the uncharged (Q18) group or mostly from the anionic (E18) group. The peptide we worked with here is the uncharged form with glutamine in the 18th position.
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Fig. 1. The two step assay. The assay consists of orthogonal measurements of peptide-
induced leakage from vesicles (step one) and access of a non-membrane permeable
quencher, dithionite, to the vesicle interiors through peptide pores at equilibrium
(step two). We assume that equilibration is reached by 8 hours. We performed two
step assays with six peptides at P:L ranging from 0.02 to 0.0005 (1:50 to 1:2000). Larger
points signify higher lipid concentration (lower P:L ratio). A: Two step assay using
100% POPC vesicles. B: Two step assay using 90:10 POPC:POPG vesicles. In each mea-
surement 1 μM peptide was used along with vesicles with entrapped terbium which
also contained 1 mol% dioleoylphosphatidylethanolamine lipid labeled on the head-
group with the dye NBD. Different lipid concentrations were used to bring the total
P:L ratio to one of the 5 values studied. After incubation, leakage of terbium was
measured as described above, followed by quenching of accessible NBD by the addition
freshly prepared dithionite. Vesicles treated with triton-X detergent were the positive
controls for all experiments. Samples with liposomes only (no peptide) were used as
negative controls. Vesicles alone (negative control) showed no detectable terbium
leakage and had NBD-quenching around 55%, corresponding to the external NBD lipids.
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peptides showed potent, equilibrium pore-formation at all concentra-
tions studied as evidenced by high leakage of terbium and high access
of the quencher to interior lipids at equilibrium indicating equilibri-
um pores. This was true at P:L ratios as low as 0.0005 (1:2000)
which is equivalent to only about 50 peptides per vesicle. In fact, ala-
methicin showsmeasurable pore-forming activity at P:L ratios as low as
0.0001 (1:10000 or 10 peptides per vesicle, see supplemental Figure S1).
Melittin formed equilibrium pores in vesicles also, but only at P:L ratios
of 0.005 (1:200) or higher. At P:L ratios ≤ 0.002 melittin's activity was
diminished, suggesting that its monomer-oligomer (pore) equilibrium,
under the conditions of these experiments, is shifted more towards
peptide monomer or another inactive form relative to alamethicin and
the LLP peptides. The elevated NBD quenchingwith low leakage that oc-
curs with melittin at low P:L suggests that melittin-dependent bilayer
disruption can increase the ﬂip-ﬂop of NBD lipids.
3.3. Bilayer disruption at low peptide concentration: the ﬂip-ﬂop assay
In the two step assay, NBD quenching greater than ~55% indicates ei-
ther that the quencher dithionite has access to the vesicle interior
through an equilibrium peptide pore or that the peptide disrupts the bi-
layer enough to allow the interior lipids to equilibrate across the mem-
brane to the outer bilayer where they can be quenched. Because
transbilayer equilibration of lipids is normally very slow (half time=
days) [20,29] rapid transbilayer equilibration of lipids (half timeb1 hour)
would require a substantial local disruption of bilayer packing and orga-
nization. A peptide that induces rapid ﬂip-ﬂop will probably be indistin-
guishable from one that forms a true pore because a disturbance to the
bilayer packing that allows the translocation of zwitterionic lipid head
groups would presumably also allow passage of other polar molecules.
To assess if lipid ﬂip-ﬂop is occurring when pore forming peptides are
present at equilibrium, we employed an equilibrium version of an assay
that we described previously [20]. In this assay, the exchangeability of a
dye-labeled lysolipid between vesicles is used to assess the rate of trans-
bilayer equilibration. We have previously shown that alamethicin and
other pore-forming peptides at high concentration cause rapid transbi-
layer equilibration of lipids immediately after addition to lipid vesicles
[20] (see supplemental ﬁgure S2). In this work, we extended the mea-
surements of ﬂip-ﬂop to vesicles containing low peptide concentrations
(P:L=0.001) that have been allowed to equilibrate before the assay.
We envision that a long-lived or stable pore, which might interact
with themembrane in away that resembles an integralmembrane pro-
tein,would cause little disruption to the packing of the bilayer lipids, es-
pecially at very low concentration. On the other hand, a dynamic pore-
forming peptide, such as one exchanging in and out of the bilayer, or
acting through a toroidal or other disordered lipid pore [30] would be
expected to catalyze ﬂip-ﬂop through local perturbation of the bilayer.
All of the pore-forming peptides studied here caused lipid ﬂip-ﬂop at
higher concentration, P:L>0.005 (P:L>1:200), immediately after addi-
tion to vesicles (supplemental Figure S2). However, after equilibration,
at low P:L=0.001 (1:1000) (Fig. 2) only alamethicin caused detectable
lipid ﬂip-ﬂop. Neither melittin nor the LLP peptides caused any
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that alamethicin pores cause a signiﬁcant and persistent local disrup-
tion of the bilayer architecture at equilibrium even at concentrations
equivalent to only a few pores per vesicle. Melittin is not very active
as a pore former at this concentration (Fig. 1), so the implications of
the lack of ﬂip-ﬂop (in the presence of melittin) are not clear. On the
other hand, the LLP peptides, like alamethicin, are very potent equilibri-
um pore formers at this concentration. Thus their lack of induced lipid
ﬂip-ﬂop indicates that active LLP pores cause much less disruption of
the bilayer than alamethicin pores under the same conditions.
3.4. Detection of exchanging pore-formers: the incremental assay
To be able to assess, in a high-throughput manner, the dynamic na-
ture of peptide pore-formation in vesicles (on a timescale of minutes to
hours)we developed the incremental leakage assay. This assaywas used
to test whether pore-forming peptides are stably embedded into lipid
bilayers or if they can exchange between membranes and permeabilize
additional vesicles. This is an important piece of information. For exam-
ple, a peptide that is in dynamic equilibrium between bilayerswould be
far less attractive as the basis for a biosensor platform than a non-
exchangeable peptide forming stably inserted or long-lived pores. On0 5 10 15 20 25 30
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Fig. 2. The Flip-ﬂop Assay. A: Example of the ﬂip-ﬂop assay in POPC vesicles using ala-
methicin. Vesicles containing 1 mol % NBD-labeled lysolipid are mixed an excess of ves-
icles containing 1 mol% rhodamine lipids, which quenches NBD ﬂuorescence. The
single chain NBD lyso-lipid can exchange rapidly from the outer monolayer of the
donor vesicles into the rhodamine (acceptor) vesicles where its ﬂuorescence is
quenched. The diacyl rhodamine lipids do not exchange. The lysolipid on the inner
monolayer does not readily equilibrate across the membrane unless the bilayer is per-
turbed. Alamethicin causes rapid transbilayer equilibration of lipids immediately upon
addition [20]. Panel A contains control experiments which show NBD-lysolipid ex-
changing between vesicles in the presence and absence of alamethicin (added at
5 min). A second addition of alamethicin at 15 min allows complete equilibration of
inner and outer monolayer lipids. B: Flip ﬂop in POPC vesicles containing pore-
forming peptides at equilibrium. Vesicles were pre-incubated for at least 8 hours
with the four pore-forming peptides studied here, allowing the peptides to reach equi-
librium. Then rhodamine-labeled vesicles were then added and exchange was moni-
tored for 10 min. Addition of alamethicin at 15 min allowed all the available NBD
lysolipid to exchange. All assays were performed at P:L=0.001 (1:1000).the other hand an exchangeable pore-former could make a more
effective toxin or cytolytic agent. Thus we must be able to distinguish
between non-exchangeable and exchangeable pores in a high through-
put manner. This can be done with the incremental assay, which
consists of a concentrated liposome solution with entrapped terbium
and external DPA added sequentially, in three separate additions, to
the same solution of peptide. Hours-long equilibration between addi-
tions is used to insure that we are examining equilibrium exchange.
Because all the peptides studied here bindwell to vesicles, there is little
free peptide remaining in the aqueous phase after the ﬁrst or second
addition. Leakage from subsequent additions of vesicles requires that
the peptides exchange between vesicles. In this incremental assay all
the peptides are highly active against the ﬁrst iteration of vesicles, but
only alamethicin and melittin were very active against subsequent
additions. The LLP peptides, which are extremely potent pore formers
at the lipid concentrations used (see Fig. 1) would cause essentially
100% leakage overall if all three vesicle increments were added at
once, but instead caused small amounts of leakage in subsequent vesicle
additions. This result indicates that the LLP peptide pores do not readily
exchange between vesicles on the timescale of several hours.
Our incremental assay results for alamethicin and melittin verify
previous reports that they exchange between vesicles on a timescale
of an hour or less [31]. Alamethicin showed 100% permeabilizing ac-
tivity against three consecutive additions of vesicles at P:L=0.001
(1:1000) (for each addition). Melittin also showed signiﬁcant leakage
from the second and third lipid additions at P:L=1:200 as well
(Fig. 3). Based on the measured partition coefﬁcients (see supple-
mental data) the fraction of peptide bound to lipid was >95% with
the initial lipid addition and higher for subsequent additions. Thus,
the amount of alamethicin or melittin in solution available for direct
partitioning into the second and third addition of vesicles is small.
The halftime of leakage against the ﬁrst increment of liposomes was
~15 min, and was ~30–45 min against the following increments.
Nonetheless, signiﬁcant leakage occurred after each increment of ves-
icles when alamethicin or melittin were used, indicating that they ex-
change between bilayers and form pores in new vesicles. We also
showed that alamethicin can exchange between, and translocate
across, the bilayers of multilamellar vesicles (MLVS, see supplemental0
20
40
60
80
100
3rd
addition
2nd
addition
%
 L
ea
ka
ge
 Alamethicin
 LLP1
 LLP2
 Melittin
1st
addition
Fig. 3. The incremental assay. A single peptide solution of 1 μM is subjected to multiple
additions of POPC/POPG (90/10) vesicles with entrapped Tb3+ and external DPA. The
leakage process for each addition of vesicles is allowed to incubate for at least
8 hours before the next addition to insure that we are examining equilibrium ex-
change. Each addition of vesicles is at P:L=0.001 (1:1000) relative to the original pep-
tide, except for the melittin experiment. Because melittin is less active overall we
performed each lipid addition for melittin at P:L=0.005 (1:200). Under these condi-
tions, all four peptides would cause signiﬁcant leakage if all increments were added
at the same time. Signiﬁcant leakage from the second or third additions of vesicles re-
quires that the peptide be able to productively exchange between vesicles. Vesicles
plus the detergent Triton-X 100 were used as a positive control and vesicles only as a
negative control.
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Fig. 4. Serial dilution assay. Alamethicin-induced leakage from POPC vesicles was mea-
sured at a set of peptide and lipid concentration corresponding to a set of six ﬁxed total
peptide:lipid ratios. The same data are plotted with different X-axes in panels A and B.
A: Leakage is shown as a function of total lipid concentration. Each curve represents a
set of experiments at the same peptide concentration. B: Leakage is shown as a function
of total peptide concentration. Each curve represents a set of experiments at the same
total peptide to lipid ratio.
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bilayers is probably prevented by its highly cationic C-terminus.
At equilibrium in bilayers, melittin is predominantly oriented par-
allel to the membrane surface [23]. The transmembrane pore is thus a
minor fraction of the total peptide. For this reason, it is not surprising
that melittin exchanges between bilayers. It is interesting to note that
alamethicin is predominantly in a transmembrane orientation in bila-
yers [32]. Yet it also exchanges readily between bilayers, suggesting
that its interaction with the membrane generates an unstable
membrane-spanning peptide-lipid structure from which the very hy-
drophobic alamethicin is able to exchange into the aqueous phase.
To further assess the mechanism of alamethicin exchange we re-
peated the incremental assay using vesicles containing 5 mol %
PEG2000-headgroup conjugated lipids, which prevents close contact
between vesicle bilayers [33]. The results were the same: alamethicin
exchanged between vesicles and caused near complete leakage in
multiple lipid additions (supplemental Figure S5A). Thus, alamethicin
exchanges between vesicles through the aqueous phase, not by vesi-
cle fusion or by contact-mediated transfer of peptide. Finally, we also
used vesicles doped with ﬂuorescent lipids to determine if lipid ex-
changes along with alamethicin (i.e. if the exchanging unit is a pep-
tide/lipid micelle). We observed no lipid exchange between vesicles
(supplemental Figure S5B). Alamethicin exchanges between vesicles
in the form of free peptide or a peptide aggregate.
3.5. Threshold concentration for dynamic exchange: the serial dilution
assay
To explore the nature of the exchanging unit of alamethicin we per-
formed a serial dilution leakage assay [34]. We measured leakage from
vesicles at a series of peptide concentrations (from 0.078 to 1.25 μM).
For each peptide concentration, we used a set of ﬁxed total P:L ratios
ranging from 0.05 to 0.001 (1:20 to 1:1000). In Fig. 4A and B we show
the observed leakage results for the alamethicin serial dilution experi-
ments plotted in two different ways: versus total peptide concentration
and versus total lipid concentration. In supplemental Figure S3 we
show, for comparison, the results of a simple numerical simulation
of a multimeric pore-forming peptide. Melittin has been shown to be-
have almost ideally in a serial dilution assay like this one [34]. While
the experiments and simulations agree at low alamethicin concentra-
tions (b400 nM), fundamental differences are apparent at higher
alamethicin concentrations. Unexpectedly, the measured activity of
alamethicin, as shown in Fig. 4B, appears to be mostly independent
of overall peptide:lipid ratio and therefore is independent of peptide
bound per lipid. For example the rightmost point of each curve in
Fig. 4A corresponds to a P:L of 0.001( 1:1000). The strong binding of
alamethicin, coupled with the same total P:L in this set of points
leads to the prediction of similar leakage activity (assuming that leak-
age is dependent on bound peptide per lipid). Yet in the actual exper-
iment, leakage in these points ranges from zero (at the lowest peptide
concentration) to 100% (at the highest peptide concentration). In-
stead of depending, as expected, on the bound P:L ratio, leakage is
more closely related to total peptide concentration. This can be seen
in the family of leakage curves in Fig. 4Bwhich all pass through amid-
point at a peptide concentration of about 3–400 nM peptide, with
only a small dependence on P:L. (see also supplemental Fig. 3B). All
of the leakage curves reach 100% leakage by 500 nM peptide, inde-
pendent of total P:L.
At low alamethicin concentration, leakage decreases when lipid
concentration is increased. This is expected, because the peptide
bound per lipid ratio is reduced, and has been observed for other
systems, including melittin [34]. Above about 400 nM, however,
alamethicin appears to switch into a mode of “continuous” activity
such that the amount of alamethicin present in a sample can permea-
bilize almost any amount of added lipid. Notice, for example, in
Fig. 4A, the dramatic difference in behavior between 400 nM and≥500 nM alamethicin. Above the critical alamethicin concentration
(400 nM) the dilution of peptide with lipid does not signiﬁcantly
diminish net leakage activity. The simulations (supplemental
Figure S3) do not predict this behavior. Most likely, the behavior
of alamethicin above the threshold occurs because the peptide can
sequentially permeabilize multiple vesicles by exchanging between
them as an aggregate of peptide.4. Discussion
4.1. Novel tools for exploring the mechanism of pore-formation in vesicles
The analytical tools described here, especially the two step and in-
cremental assays, can be used in a high-throughput format at very low
peptide concentration to select for peptides that assemble into po-
tent, non-exchanging equilibrium pores that would be suitable for
biosensor applications, for example. Alternately they could be used
to select for dynamic, exchanging pores that would, perhaps be highly
potent cytotoxins. Although we performed the two step and incremen-
tal assays separately here, they can be combined into a single high-
throughput assay. The novel two step assay provides a uniquely useful
tool to study pore-forming peptides by allowing us to probe their
potency and the functional state of the peptide pore after leakage
1631A.J. Krauson et al. / Biochimica et Biophysica Acta 1818 (2012) 1625–1632has taken place and after the peptide bilayer system has reached
equilibration. We used the two step assay to verify that the antimicro-
bial peptides do not form equilibrium pores in vesicles, but instead
cause short-lived, transient leakage events as we have discussed else-
where [9,10]. It also showed that alamethicin and the LLP peptides are
extremely potent and form equilibrium pores in lipid vesicles at P:L
lower than P:L=0.0005 (P:L=1:2000 or 50 peptides per vesicle).
These pores can be detected even after equilibration. The comple-
mentary incremental assay allows us to assess the dynamic nature of
membrane binding and pore formation by peptides on time scale of
minutes to hours, by assessing the exchangeability of pore forming
peptides at equilibrium. This is an important consideration for bio-
sensor design in which stable insertion is desired. The ﬂip ﬂop and
serial dilution assays are not amenable to high throughput screening,
but will be extremely useful, post-selection, to characterize peptide-
induced perturbation of the bilayer architecture and to assess the
mode of activity of pore forming peptides selected using the two-
step and incremental assays.
4.2. Classes of membrane permeabilizing peptides
With the assays developed for this work it is possible to easily rec-
ognize at least three mechanistic classes of membrane permeabilizing
peptides. Importantly for our future work, these techniques can also
be used for high throughput screening to select for speciﬁc classes
of membrane permeabilizing peptides. The antimicrobial peptides
we studied here are not potent membrane-permeabilizing peptides
and do not form equilibrium pores in membranes, even in anionic
membranes. This is the typical behavior for many antimicrobial pep-
tides [9,10,35] and is probably related to their need to be selective
for bacterial versus eukaryotic membranes. Explicit equilibrium,
transmembrane pores have been reported for LL37 [36], but we
observe no evidence of transmembrane pores under any condition.
Alamethicin and melittin are two of the most thoroughly studied
pore forming peptides known. Their pore structure and the dynamic
nature of their pore formation in membranes have been thoroughly de-
scribed in the literature [13,22,23,37-40]. Hereweused them to validate
the assays developed for this work and to extend our description of
their pore formation to low concentration, equilibrium conditions.
Consistent with reports on alamethicin in the presence of a transmem-
brane potential [21,31]we found that alamethicin is especially dynamic,
exchanging in and out of membranes and causing very signiﬁcant
disruption of lipid packing and bilayer architecture at equilibrium,
even at P:L ratios as low as 1:1000, or 100 peptides per vesicle.
In terms of our goal of designing stably inserted peptide pores, ala-
methicin is an excellent example of the type of behavior we will have
to select against. On the other hand, the lentivirus lytic peptides show
the type of behavior we would be selecting for in a screen for stable
pore formers. They are extremely potent, and create equilibrium
pores in bilayers at low concentration. But unlike alamethicin, the LLP
peptides do not exchange readily between bilayers and do not perturb
the bilayer packing and organization at equilibrium. Additional focused
studies are underway to examine the structure and detailedmechanism
of the LLP pores in membranes.
5. Conclusions
Here we have described a set of novel experimental tools that we
used to probe the character and dynamics of three classes of pore-
forming peptides in lipid vesicles at low concentration, at equilibrium,
and at time-scales that have not frequently been explored. With
these techniques, we can easily distinguish between various classes of
membrane-permeabilizing peptides (e.g. transient pores, dynamic equi-
librium pores, stable equilibrium pores). Importantly for our long-term
goals, these methods can be used to select for pore forming peptides be-
longing to any of the speciﬁc classes discussed here.Acknowledgements
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